Compare FIBK & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIBK | CDNA |
|---|---|---|
| Founded | 1879 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.3B |
| IPO Year | 1997 | 2007 |
| Metric | FIBK | CDNA |
|---|---|---|
| Price | $37.60 | $68.72 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 7 |
| Target Price | $37.50 | ★ $64.17 |
| AVG Volume (30 Days) | 1.0M | ★ 1.3M |
| Earning Date | 10-22-2026 | 10-29-2026 |
| Dividend Yield | ★ 5.11% | N/A |
| EPS Growth | ★ 34.25 | N/A |
| EPS | 1.47 | ★ 2.13 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | N/A | $30.36 |
| Revenue Next Year | $2.17 | $6.23 |
| P/E Ratio | ★ $25.07 | $32.46 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $29.39 | $14.23 |
| 52 Week High | $40.60 | $72.71 |
| Indicator | FIBK | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 65.86 | 61.51 |
| Support Level | $36.85 | $17.30 |
| Resistance Level | $37.75 | $72.51 |
| Average True Range (ATR) | 0.71 | 3.95 |
| MACD | 0.36 | -0.16 |
| Stochastic Oscillator | 96.82 | 64.67 |
First Interstate BancSystem Inc is a financial holding company. It is the parent company of First Interstate Bank, a community bank offering a range of internet, mobile, and other banking and financial services throughout Idaho, Montana, Oregon, South Dakota, Washington, and Wyoming. It delivers a range of financial products and services to both retail and commercial customers in industries like agriculture, construction, education, energy, governmental services, healthcare, mining, professional services, retail, tourism and wholesale trade. It generates majority of income from interest charged on loans, and interest and dividends earned on investments.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.